François Tronc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
François Tronc has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Gabrielle Drevet
Department of Thoracic Surgery, Lung and Heart-Lung Transplantation, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
4 shared publications - Jean-Michel Maury
Department of Thoracic Surgery, Lung and Heart-Lung Transplantation, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France
4 shared publications - Lara Chalabreysse
Hospices civils de Lyon groupement hospitalier Est, université Claude-Bernard Lyon 1, Lyon, France
3 shared publications Alessandro Orsini
Department of Thoracic Surgery , Hopital Louis Pradel , Lyon , France
2 shared publicationsGabrielle Drevet
2 shared publications- Nicolas Girard
Institut Curie
2 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 7886-7895
Modalities of follow-up after surgical plication for diaphragmatic paralysis
Background: Treatment of symptomatic diaphragmatic paralysis by surgical diaphragm plication provides relief to many patients, but there are no guidelines for follow-up. The aim of our study is to evaluate long-term results of diaphragm plication and to outline follow-up modalities. Methods: We conducted a retrospective monocentric study including all the patients with unilateral diaphragmatic paralysis (UDP) consecutively operated between January 2006 and December 2021. Benefits of surgery were evaluated on dyspnea, spirometry and repeated measurements of the distance from apex to diaphragm (A-D) on chest X-ray. Results: A total of 23 patients were included; 60% were women. Etiology of diaphragmatic eventration was idiopathic in 14 patients (61%), iatrogenic in 3 patients (13%) and post-traumatic in 6 patients (26%). All patients had dyspnea at diagnosis with a significant reduction of vital capacity (VC) from seated to supine position, decreasing from 71.2%±18.7% to 59%±26.5% (P=0.002). All patients were operated by thoracotomy with an average hospital stay of 7.7±5 days. No postoperative mortality was observed. Median follow-up was 19 months. There was a statistically significant (P=0.001) improvement in the Medical Research Council (MRC) dyspnea score at 6 months persistent at last follow-up. VC improved from 71.2%±18.7% to 88.1%±19.4% at last follow-up (P=0.03). Chest X-ray showed a significant increase in the A-D distance from 12±3.2 to 19±2.8 cm at 6 months (P=0.001) and 17.9±3.59 cm at remote (P=0.001). A significant correlation was found between A-D distance and dyspnea, but not between X-ray measurements and VC. Conclusions: Diaphragm plication effectively alleviates dyspnea in patients with diaphragmatic paralysis. Good functional results are persistent at 2 years. The correlation between chest X-ray and dyspnea suggests that these parameters may suffice for follow-up.
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 7886-7895
Open AccessModalities of follow-up after surgical plication for diaphragmatic paralysis
Background: Treatment of symptomatic diaphragmatic paralysis by surgical diaphragm plication provides relief to many patients, but there are no guidelines for follow-up. The aim of our study is to evaluate long-term results of diaphragm plication and to outline follow-up modalities. Methods: We conducted a retrospective monocentric study including all the patients with unilateral diaphragmatic paralysis (UDP) consecutively operated between January 2006 and December 2021. Benefits of surgery were evaluated on dyspnea, spirometry and repeated measurements of the distance from apex to diaphragm (A-D) on chest X-ray. Results: A total of 23 patients were included; 60% were women. Etiology of diaphragmatic eventration was idiopathic in 14 patients (61%), iatrogenic in 3 patients (13%) and post-traumatic in 6 patients (26%). All patients had dyspnea at diagnosis with a significant reduction of vital capacity (VC) from seated to supine position, decreasing from 71.2%±18.7% to 59%±26.5% (P=0.002). All patients were operated by thoracotomy with an average hospital stay of 7.7±5 days. No postoperative mortality was observed. Median follow-up was 19 months. There was a statistically significant (P=0.001) improvement in the Medical Research Council (MRC) dyspnea score at 6 months persistent at last follow-up. VC improved from 71.2%±18.7% to 88.1%±19.4% at last follow-up (P=0.03). Chest X-ray showed a significant increase in the A-D distance from 12±3.2 to 19±2.8 cm at 6 months (P=0.001) and 17.9±3.59 cm at remote (P=0.001). A significant correlation was found between A-D distance and dyspnea, but not between X-ray measurements and VC. Conclusions: Diaphragm plication effectively alleviates dyspnea in patients with diaphragmatic paralysis. Good functional results are persistent at 2 years. The correlation between chest X-ray and dyspnea suggests that these parameters may suffice for follow-up.
- Open Access
Subtotal Pleurectomy with Intrathoracic Chemo Hyperthermia (HITHOC) for IVa Thymomas: De Novo Versus Recurrent Pleural Disease
Introduction: Stage IVa thymoma is a rare disease without a standard of care. Subtotal pleurectomy and HITHOC introduced in highly selected patients may provide interesting oncologic results. The purpose of this study was to distinguish de novo stage IVa tumors (DNT) from distant relapse (DR) with respect to post-operative and long-term outcomes to provide the procedure efficacy. Methods: From July 1997–December 2021, 40 patients with IVa pleural involvement were retrospectively analyzed. The surgical procedure was subtotal pleurectomy and HITHOC (cisplatin 50 mg/m2, mitomycin 25 mg/m2, 42 °C, 90 min). The post-operative outcome, disease-free interval (DFI) and overall survival (OS) were analyzed. Results: Mean age was 52 ± 12 years. B2 and B3 thymomas were preponderant (27; 67.5%). The median number of pleural nodes were nine (4–81) vs. five (1–36); p = 0.004 * in DNT and DR, respectively. Hospital mortality rate was 2.5%. There were four specific HITHOC complications (10%). DFI were 49 and 85 months (p = 0.02 *), OS were 94 and 118 months (NS), in DNT and DR, respectively. Conclusions: Subtotal pleurectomy with HITHOC in IVa offers satisfying results in highly selected patients, for both DNT and DR. Due to the disease rarity, multicentric studies are needed to define HITHOC as a standard of care.
Open AccessSubtotal Pleurectomy with Intrathoracic Chemo Hyperthermia (HITHOC) for IVa Thymomas: De Novo Versus Recurrent Pleural Disease
Introduction: Stage IVa thymoma is a rare disease without a standard of care. Subtotal pleurectomy and HITHOC introduced in highly selected patients may provide interesting oncologic results. The purpose of this study was to distinguish de novo stage IVa tumors (DNT) from distant relapse (DR) with respect to post-operative and long-term outcomes to provide the procedure efficacy. Methods: From July 1997–December 2021, 40 patients with IVa pleural involvement were retrospectively analyzed. The surgical procedure was subtotal pleurectomy and HITHOC (cisplatin 50 mg/m2, mitomycin 25 mg/m2, 42 °C, 90 min). The post-operative outcome, disease-free interval (DFI) and overall survival (OS) were analyzed. Results: Mean age was 52 ± 12 years. B2 and B3 thymomas were preponderant (27; 67.5%). The median number of pleural nodes were nine (4–81) vs. five (1–36); p = 0.004 * in DNT and DR, respectively. Hospital mortality rate was 2.5%. There were four specific HITHOC complications (10%). DFI were 49 and 85 months (p = 0.02 *), OS were 94 and 118 months (NS), in DNT and DR, respectively. Conclusions: Subtotal pleurectomy with HITHOC in IVa offers satisfying results in highly selected patients, for both DNT and DR. Due to the disease rarity, multicentric studies are needed to define HITHOC as a standard of care.
- Open Access
- 11 May 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3489-3493
Hamartochondroma Pleural Lesion Mimicking Liposarcoma: A Case Report
Heterogeneous masses developing in the pleural cavity are most often malignant and can pose diagnostic challenges. Fibrous tumors of the pleura, liposarcoma, thymoma or lipoma most frequently affect this anatomic area. Surgical exploration and resection are often mandatory to make the definitive diagnosis. We report the case of a 54-year-old women who presented with an epigastric and right sub costal pain. A complete preoperative workup revealed a large tissular and fatty mass in the right costo-diaphragmatic angle suggestive of liposarcoma. Surgical resection resulted in the surprising diagnosis of hamartochondroma.
- 11 May 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3489-3493
Open AccessHamartochondroma Pleural Lesion Mimicking Liposarcoma: A Case Report
Heterogeneous masses developing in the pleural cavity are most often malignant and can pose diagnostic challenges. Fibrous tumors of the pleura, liposarcoma, thymoma or lipoma most frequently affect this anatomic area. Surgical exploration and resection are often mandatory to make the definitive diagnosis. We report the case of a 54-year-old women who presented with an epigastric and right sub costal pain. A complete preoperative workup revealed a large tissular and fatty mass in the right costo-diaphragmatic angle suggestive of liposarcoma. Surgical resection resulted in the surprising diagnosis of hamartochondroma.
- Open Access
- 26 April 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3061-3071
Evolution of the Surgical Management of Lung Cancer Invading the Spine: A Single Center Experience
For patients with locally advanced non-small cell lung cancer invading the spine, induction chemoradiotherapy combined with radical en bloc resection is the key to obtaining long-term survival. With time, our operative technique evolved to a two-step surgery as we experienced numerous perioperative complications during one step surgery. The aim of our study was to assess postoperative morbimortality and long-term survival of both techniques. We retrospectively reviewed all patients who underwent en bloc resection for lung cancer invading the spine between October 2012 and June 2020. Every patient underwent induction therapy. Sixteen patients were included: nine patients were operated on with one step surgery, seven patients were operated on with two step interventions. Twenty-five percent of patients had major perioperative complications and 56.2% of patients had major post-operative complications. Patients in the “one step” group tended to have more perioperative complications whereas patients in the “two step” group tended to have more post-operative complications. Overall 3-year survival was 40% in the one-step and 86% in the two-step surgery group. Although our practice has been improved by two-step interventions, post-operative morbidity remains significant. As long term survivals are encouraging, this type of treatment should still be proposed for highly selected patients, in specialized centers.
- 26 April 2022
- Published by MDPI AG in Current Oncology
- Vol. 29 (5) , 3061-3071
Open AccessEvolution of the Surgical Management of Lung Cancer Invading the Spine: A Single Center Experience
For patients with locally advanced non-small cell lung cancer invading the spine, induction chemoradiotherapy combined with radical en bloc resection is the key to obtaining long-term survival. With time, our operative technique evolved to a two-step surgery as we experienced numerous perioperative complications during one step surgery. The aim of our study was to assess postoperative morbimortality and long-term survival of both techniques. We retrospectively reviewed all patients who underwent en bloc resection for lung cancer invading the spine between October 2012 and June 2020. Every patient underwent induction therapy. Sixteen patients were included: nine patients were operated on with one step surgery, seven patients were operated on with two step interventions. Twenty-five percent of patients had major perioperative complications and 56.2% of patients had major post-operative complications. Patients in the “one step” group tended to have more perioperative complications whereas patients in the “two step” group tended to have more post-operative complications. Overall 3-year survival was 40% in the one-step and 86% in the two-step surgery group. Although our practice has been improved by two-step interventions, post-operative morbidity remains significant. As long term survivals are encouraging, this type of treatment should still be proposed for highly selected patients, in specialized centers.
- Open Access
Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL)
This article presents the protective measures put in place at the “Institut de Cancérologie des Hospices de Lyon” (IC-HCL) during the first wave of the COVID-19 pandemic in France (spring 2020) and how they impacted IC-HCL clinical activity. Spring 2020 activities were compared to winter 2019–2020. Results showed a decrease of activity of 9% for treatment dispensations, 17% for multidisciplinary team meetings, 20% for head and neck and thoracic surgeries, and 58% for new patient enrolment in clinical trials. Characteristics of patients treated for solid cancer and hospitalized for COVID-19 during spring 2020 were collected in a retrospective study. Mortality was attributed to COVID-19 for half of the cases, 82% being patients above 70 and 73% being stage IV. This is in concordance with current findings concluding that the risk of developing severe or critical symptoms of COVID-19 is correlated with factors co-occurring in cancer patients and not to the cancer condition per se. While a number of routines and treatment regimens were changed, there was no major decline in numbers of treatments conducted at the IC-HCL during the first wave of the COVID-19 pandemic that hit France between March and May 2020, except for clinical trials and some surgery activities.
Open AccessImpact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL)
This article presents the protective measures put in place at the “Institut de Cancérologie des Hospices de Lyon” (IC-HCL) during the first wave of the COVID-19 pandemic in France (spring 2020) and how they impacted IC-HCL clinical activity. Spring 2020 activities were compared to winter 2019–2020. Results showed a decrease of activity of 9% for treatment dispensations, 17% for multidisciplinary team meetings, 20% for head and neck and thoracic surgeries, and 58% for new patient enrolment in clinical trials. Characteristics of patients treated for solid cancer and hospitalized for COVID-19 during spring 2020 were collected in a retrospective study. Mortality was attributed to COVID-19 for half of the cases, 82% being patients above 70 and 73% being stage IV. This is in concordance with current findings concluding that the risk of developing severe or critical symptoms of COVID-19 is correlated with factors co-occurring in cancer patients and not to the cancer condition per se. While a number of routines and treatment regimens were changed, there was no major decline in numbers of treatments conducted at the IC-HCL during the first wave of the COVID-19 pandemic that hit France between March and May 2020, except for clinical trials and some surgery activities.
- 1 October 2021
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 50 (8) , 102147
Surgical management of diaphragmatic and thoracic endometriosis’: A French multicentric descriptive study
- 1 October 2021
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 50 (8) , 102147
Surgical management of diaphragmatic and thoracic endometriosis’: A French multicentric descriptive study
- Open Access
- 1 August 2021
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 71, 101884
Persistent left superior vena cava with patent left innominate vein: Ideal anatomy for mini invasive thoracoscopic ligature
- 1 August 2021
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 71, 101884
Open AccessPersistent left superior vena cava with patent left innominate vein: Ideal anatomy for mini invasive thoracoscopic ligature
- Open Access
Pleuropneumonectomy as Salvage Therapy in Children Suffering from Primary or Metastatic Sarcomas with Pleural Localizations
Pediatric sarcoma patients with pleuropulmonary lesions have a dismal prognosis because the impossibility to obtain local control. The aim of this study was to determine if pleuropneumonectomy (PP) could be a therapeutic option. We retrospectively reviewed nine patients who underwent salvage PP for pleuropulmonary localization of primary localized sarcoma or metastatic recurrence. Surgery and complications were analyzed, pulmonary function tests were conducted, and quality of life was determined with EORTC-QLQ-C30 questionnaire. At the time of PP age was between 9–17 years. Underlying disease included metastatic osteosarcoma (n = 5), Ewing sarcoma (two metastatic, one primary), and one primary undifferentiated sarcoma. Early complications occurred in three patients. Mean postoperative hospitalization stay was 14.5 days. Pulmonary function test showed 19–66% reduction of total lung capacity which led to mild exercise intolerance but did not affect daily life. Four patients died of multi-metastatic relapse <14 months after PP, one patient had a local recurrence, and four patients are in complete remission between 1.5 and 12 years after PP. In conclusion, in this small patient group treated with a pleuropneumonectomy for primary or metastatic lesions, outcome is variable; however, this extended surgical technique was generally quite well tolerated. Postoperative lung function seems well preserved, and it seems to lead to at least an extension of life with good quality and therefor can be considered as salvage therapy.
Open AccessPleuropneumonectomy as Salvage Therapy in Children Suffering from Primary or Metastatic Sarcomas with Pleural Localizations
Pediatric sarcoma patients with pleuropulmonary lesions have a dismal prognosis because the impossibility to obtain local control. The aim of this study was to determine if pleuropneumonectomy (PP) could be a therapeutic option. We retrospectively reviewed nine patients who underwent salvage PP for pleuropulmonary localization of primary localized sarcoma or metastatic recurrence. Surgery and complications were analyzed, pulmonary function tests were conducted, and quality of life was determined with EORTC-QLQ-C30 questionnaire. At the time of PP age was between 9–17 years. Underlying disease included metastatic osteosarcoma (n = 5), Ewing sarcoma (two metastatic, one primary), and one primary undifferentiated sarcoma. Early complications occurred in three patients. Mean postoperative hospitalization stay was 14.5 days. Pulmonary function test showed 19–66% reduction of total lung capacity which led to mild exercise intolerance but did not affect daily life. Four patients died of multi-metastatic relapse <14 months after PP, one patient had a local recurrence, and four patients are in complete remission between 1.5 and 12 years after PP. In conclusion, in this small patient group treated with a pleuropneumonectomy for primary or metastatic lesions, outcome is variable; however, this extended surgical technique was generally quite well tolerated. Postoperative lung function seems well preserved, and it seems to lead to at least an extension of life with good quality and therefor can be considered as salvage therapy.
- 1 November 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (9) , 2820-2823
Combined Single Lung and Liver Transplantation in a Cystic Fibrosis Patient With Previous Contralateral Pneumonectomy: A Case Report
- 1 November 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (9) , 2820-2823
Combined Single Lung and Liver Transplantation in a Cystic Fibrosis Patient With Previous Contralateral Pneumonectomy: A Case Report
- Open Access
Activation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas
The pathogenesis of thymic epithelial tumors remains poorly elucidated. The PI3K/Akt/mTOR pathway plays a key role in various cancers; interestingly, several phase I/II study reported a positive effect of mTOR inhibitors in disease control in thymoma patients. A major limit for deciphering cellular and molecular events leading to the transformation of thymic epithelial cells or for testing drug candidates is the lack of reliable in vitro cell system We analyzed protein expression and activation of key players of the Akt/mTOR pathway namely Akt, mTOR, and P70S6K in thirteen A, B and AB thymomas as well as in normal thymuses. While only Akt and the phospho-Akt were expressed in normal thymuses, both Akt and mTOR were activated, with B2 thymomas expressing higher level of activated phospho-Akt than A or AB subtypes. Phospho-P70S6K was expressed in all thymic tumors whatever their subtypes, and absent in normal thymus. Interestingly, in primary thymic epithelial cells maintained for short period of time after their derivation from seven AB and B thymomas, we report the activation of Akt; mTOR and P70S6. Finally, we analyzed the effect of mTOR inhibitor on thymoma derived epithelial cells and showed that rapamycin (100 nM/ ml) significantly reduced cell proliferation. Our results suggest that the activation of the Akt/ mTOR pathway might participate to the cell proliferation associated with tumor growth. Ultimately, our data enhance the potential role of thymic epithelial cells derived from tissue specimens for in vitro exploration of molecular abnormalities specific to rare thymic tumors.
Open AccessActivation of the mTOR/ Akt pathway in thymic epithelial cells derived from thymomas
The pathogenesis of thymic epithelial tumors remains poorly elucidated. The PI3K/Akt/mTOR pathway plays a key role in various cancers; interestingly, several phase I/II study reported a positive effect of mTOR inhibitors in disease control in thymoma patients. A major limit for deciphering cellular and molecular events leading to the transformation of thymic epithelial cells or for testing drug candidates is the lack of reliable in vitro cell system We analyzed protein expression and activation of key players of the Akt/mTOR pathway namely Akt, mTOR, and P70S6K in thirteen A, B and AB thymomas as well as in normal thymuses. While only Akt and the phospho-Akt were expressed in normal thymuses, both Akt and mTOR were activated, with B2 thymomas expressing higher level of activated phospho-Akt than A or AB subtypes. Phospho-P70S6K was expressed in all thymic tumors whatever their subtypes, and absent in normal thymus. Interestingly, in primary thymic epithelial cells maintained for short period of time after their derivation from seven AB and B thymomas, we report the activation of Akt; mTOR and P70S6. Finally, we analyzed the effect of mTOR inhibitor on thymoma derived epithelial cells and showed that rapamycin (100 nM/ ml) significantly reduced cell proliferation. Our results suggest that the activation of the Akt/ mTOR pathway might participate to the cell proliferation associated with tumor growth. Ultimately, our data enhance the potential role of thymic epithelial cells derived from tissue specimens for in vitro exploration of molecular abnormalities specific to rare thymic tumors.